Latest Content

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Psychiatric Times embraces innovation with interactive digital issues and a new print format, enhancing accessibility for psychiatric clinicians.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Psychiatric Times is adapting to the evolving media landscape, focusing on impactful stories and insights, starting with schizophrenia and lifestyle psychiatry.

Psychiatry is the medical specialty that wrestles with the included middle—requiring judgment, patience, and humility.

These are the 2 winners of the Hanusol Contest!

Explore the vital role of consultation liaison psychiatry in enhancing patient care and emotional well-being in complex medical conditions in our January 2026 theme!

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

MapLight Therapeutics advances treatment for Alzheimer disease psychosis with FDA Fast Track designation for ML-007C-MA, targeting hallucinations and delusions.

Integrating arts and humanities into psychiatry enhances patient recovery, fosters connectedness, and enriches clinician engagement, transforming mental health care.